Sign in Subscribe
Pricing Policies

Pricing Policies

Timely insights into the evolving pricing framework and policy levers shaping market access for medical technologies throughout their life cycle.
Jun
20
NHSA Consults on 2025 Dual-List Adjustment Work Plan for NRDL and Commercial Drug List

NHSA Consults on 2025 Dual-List Adjustment Work Plan for NRDL and Commercial Drug List

The Dual-List Adjustment Mechanism marks a pivotal shift in China’s reimbursement system, prompting key strategic questions for innovative drug makers.
5 min read
Jan
02
The Future of Innovative Medicine Pricing and Reimbursement in China: Signals from the 2024 NRDL Negotiations

The Future of Innovative Medicine Pricing and Reimbursement in China: Signals from the 2024 NRDL Negotiations

These developments call for a global pricing strategy rooted in China's evolving reimbursement infrastructure, breaking siloed thinking to balance short-term goals with long-term growth.
9 min read
Dec
04
NHSA Strengthens Control Over Outpatient Spending

NHSA Strengthens Control Over Outpatient Spending

Effectively navigating these regulatory changes will have significant and lasting implications for drug manufacturers, particularly in shaping their pricing strategies, reimbursement models, and distribution channel approaches in China.
7 min read
Aug
28
Three Key Trends Shaping Pricing for Innovative Non-VBP Medical Devices in China

Three Key Trends Shaping Pricing for Innovative Non-VBP Medical Devices in China

Understanding and strategically applying these trends is crucial for optimizing pricing strategies and enhancing market adoption of innovative medical technologies in China.
7 min read
May
08
Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations

Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations

These perspectives provide unique insights into what may contribute to NHSA's decision criteria in pricing medical innovations and allocating healthcare resources.
5 min read
May
01
Advancements in China's BMI Payment Policies for High-Value Medical Consumables: How MedTech Should Prepare

Advancements in China's BMI Payment Policies for High-Value Medical Consumables: How MedTech Should Prepare

These policies create a national framework for the pricing and reimbursement of high-value medical consumables under basic medical insurance schemes, necessitating proactive preparedness from MedTech firms.
6 min read
Apr
17
Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing

Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing

The standout enhancement in the current proposal is the addition of a self-assessment scale. This tool, designed to assign a score that quantifies innovation quality based on the company's self-assessment, plays a crucial role in determining the initial pricing of their drugs.
10 min read
Mar
27
Pudong Drug Pricing Pilot

Pudong Drug Pricing Pilot

#1 Pudong reform pilot permits new drug launch pricing comparable to international markets. On January 22nd, a joint announcement was
3 min read
Jan
03
Fair Pricing of Pharmaceuticals: Insights into China's NRDL Negotiation

Fair Pricing of Pharmaceuticals: Insights into China's NRDL Negotiation

Although NRDL negotiation involves multiple aspects, at its core, the most fundamental issue is the fair pricing of innovative pharmaceuticals.
5 min read
Dec
06
NHSA Proposes Launch Price Framework and Aligns Pricing Policies with Drug Lifecycle

NHSA Proposes Launch Price Framework and Aligns Pricing Policies with Drug Lifecycle

At a recent industry investor conference, Weng Linjia, Deputy Director of the Pharmaceutical Pricing and Tender Procurement Department, National Healthcare
4 min read